Boothbay Fund Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Boothbay Fund Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-995	Closed	-$28K	–	2788
2022 Q1	$28K	Hold	995	–	–	﹤0.01%	2221
2021 Q4	$45K	Hold	995	–	–	﹤0.01%	1778
2021 Q3	$83K	Sell	995 -51	-5%	-$4.22K	﹤0.01%	1819
2021 Q2	$99K	Sell	1,046 -1,360	-57%	-$161K	﹤0.01%	1741
2021 Q1	$400K	Sell	2,406 -4,567	-65%	-$604K	0.02%	1059
2020 Q4	$683K	Buy	+6,973	New	+$441K	0.03%	635

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Boothbay Fund Management's ONCT Position: Q2 2022 in Review

Boothbay Fund Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q2 2022, closing a stake of 995 shares — an estimated $28K sold.

Boothbay Fund Management first reported a position in ONCT in Q4 2020 and held it in 6 quarters. The position peaked at $683K in Q4 2020. 75 funds tracked by Wall St. Rank hold ONCT as of Q2 2022.

Boothbay Fund Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Boothbay Fund Management sold 995 Oncternal Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $28K.
Boothbay Fund Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Boothbay Fund Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $683K in Q4 2020.
75 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Boothbay Fund Management's 13F filing for Q2 2022, filed 15 Aug 2022.